Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.04
<AU$0.01(9.09%)
At close: 4:00 PM EDT
AU$0.04
<AU$0.01(9.09%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.08
Previous CloseN/A
Volume920.05K
Average Volume (3M)1.89M
Market Cap
AU$31.46M
Enterprise ValueAU$25.76M
Total Cash (Recent Filing)AU$7.29M
Total Debt (Recent Filing)AU$787.38K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,686,040
10 Day Avg. Volume1,315,341
30 Day Avg. Volume1,885,519
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.35
Price to Sales (P/S)7.63
P/FCF Ratio-6.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.70M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2026 revenue rebound indicates renewed commercial activity across the company’s mental-health services and development platform. If sustained, stronger top-line scale could improve operating leverage, support reinvestment in therapeutics, and strengthen the company’s ability to build a more durable healthcare business.
Low LeverageA materially lower debt-to-equity ratio provides greater financial flexibility than the company had in 2024. Modest leverage reduces pressure from debt servicing and leaves more strategic room to fund clinical development, maintain operations, or respond to changing conditions without excessive balance-sheet strain.
Integrated Healthcare PlatformThe combination of direct mental-health services, clinical research, and therapeutic development gives Emyria multiple ways to participate in the care pathway. This integrated platform can support knowledge transfer between services and research while broadening the company’s longer-term growth opportunities.
Bears Say
Persistent UnprofitabilityPersistent net losses and deeply negative margins show that revenue has not yet translated into an economically sustainable operating model. Continued costs running ahead of revenue can constrain investment capacity, weaken retained equity, and make future growth dependent on improving execution and cost absorption.
Cash BurnOngoing negative operating and free cash flow means the business is consuming cash rather than self-funding its activities. Substantial annual burn can increase reliance on cash reserves or external funding, potentially limiting strategic flexibility and creating pressure to secure capital while development work continues.
Negative Shareholder ReturnsNegative return on equity indicates that the company is currently eroding shareholder value through losses rather than generating returns from its capital base. Unless profitability improves, the stronger balance-sheet position may continue to be offset by declining equity efficiency and limited internal capital generation.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.04 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$31.46M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 129 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Aug 31, 2026. The company reported -AU$0.005 earnings per share for the quarter.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,686,040 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.005 in its last earnings report. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.09%
12-Months-Change
Fundamentals
Return on Equity
-58.38%
Trailing 12-Months
Asset Growth
73.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Emyria Ltd
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
―